494795-55-0

Upstream product

• 5570-19-4 2-nitrophenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 577-19-5 2-nitrophenyl bromide 
• 88-73-3 2-Chloronitrobenzene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 955397-70-3 4-(2-aminophenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 
• 1274933-97-9 4-(2-nitro-phenyl)-1,2,3,6-tetrahydro-pyridine hydrochloride 
• 1274933-98-0 1-[4-(2-nitro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]ethanone 
• 1274933-99-1 1-[4-(2-amino-phenyl)-piperidin-1-yl]-ethanone 
• 1274934-00-7 1-[4-(2-chloro-phenyl)-piperidin-1-yl]-ethanone 
• 82211-92-5 4-(2-chloro-phenyl)piperidine hydrochloride 
• 199105-03-8 tert-butyl 4-(2-aminophenyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1

Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.

Substituted piperidines and methods of use

Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.